胸腺肽辅助治疗对糖尿病合并肺结核患者治疗效果及血清中免疫细胞水平的影响

胸腺肽辅助治疗对糖尿病合并肺结核患者治疗效果及血清中免疫细胞水平的影响(论文4700字)
【摘要】　目的　探讨胸腺肽注射液辅助治疗糖尿病合并肺结核患者的临床效果及患者血清中免疫细胞水平的影响。 方法　选取本院2014年6月至2016年6月在院治疗，经T-spot.TB诊断为结核潜在感染的糖尿病患者98例，根据患者自愿原则分为采用常规治疗的对照组和联合胸腺肽辅助治疗的对照组，对比两组患者结核治疗效果、血清中免疫细胞水平。结果：　观察组患者强化期结束、疗程结束涂阳转阴分别为37、42例，培养转阴分别为36例、41例，与对照组患者数据比较无差异，P>0.05；对比不同类型患者血清中免疫细胞水平，结果发现正常人群血清中Treg细胞水平为1.3±0.6，明显低于糖尿病和糖尿病合并肺结核患者，而Th17细胞水平为3.5±1.2，明显高于糖尿病患者和糖尿病合并肺结核患者，差异显著，具有统计学意义；两组患者治疗前Treg细胞核Th17细胞水平对比无差异，具有可比性，随着治疗的进展Treg细胞含量依次下降，但观察组患者强化期结束和疗程结束Treg含量分别为2.2±0.8、1.7±0.5，相比含量低于对照组，Th17细胞含量逐渐上升，但是观察组患者强化期结束和疗程结束Th17细胞含量分别为2.5±0.6，3.1±0.7，明显高于对照组患者，差异显著，具有统计学意义；两组患者治疗后症状发生情况对比无差异，治疗后观察组患者乏力、盗汗、食欲下降、咳嗽、咳痰消失率分别为88.89%、87.10%、86.36%、75.0%、88.89%，明显高于对照组，差异显著，具有统计学意义。结论：在强化抗痨治疗的同时采用胸腺肽注射辅助提高患者免疫功能，有助于改善患者T细胞亚群，促进患者临床症状的缓解，值得临床推广运用。
【关键词】　胸腺肽；糖尿病合并肺结核；效果；免疫
Effect of immune cells and serum level of clinical effect in patients with Thymopeptide Enteric Injection adjuvant treatment of diabetes complicated with pulmonary tuberculosis
[Abstract] Objective  To investigate the effect of immune cells and serum level of clinical effect in patients with Thymopeptide Enteric Injection adjuvant treatment of diabetes complicated with pulmonary tuberculosis..Methods 98 cases of diabetic patients with tuberculosis infection in our hospital from June 2014 to June 2016 , diagnosed by T-spot.TB in , according to the principle of voluntary patients were divided into the control group and the control group with conventional therapy combined with thymosin adjuvant therapy, immune cell level contrast effect, the treatment group of two patients with tuberculosis in serum.Result：Patients in the observation group at the end of the end of the treatment, strengthening the smear negative were 37, 42 cases were culture negative were 36 cases, 41 cases had no difference compared with the control group, the patient data P>0.05; serum levels of immune cells in patients with different types of contrast, found that the normal serum level of Treg cells was 1.3±.6. Was significantly lower than that in patients with diabetes and diabetes combined with pulmonary tuberculosis, and the level of Th17 cells was 3.5± 1.2, significantly higher than in patients with diabetes and diabetes combined with pulmonary tuberculosis was significantly different, with statistical significance; the two groups were compared before Treg cell nuclear Th17 cells had no significant difference, comparable with the progress in the treatment of Treg cells in order to decrease, but the patients in the observation group enhanced Treg content and the end of treatment were 2.2± 0.8, 1.7± 0.5, compared were lower than control group, Th17 cell content Increased gradually, but the patients in the observation group were enhanced Th17 cells content end and course of treatment were 2.5±0.6, 3.1± 0.7, significantly higher than in the control group, the difference was statistically significant; two groups of patients after treatment of symptoms compared to no difference, the observation group after treatment in patients with fatigue, sweating, loss of appetite, cough and sputum disappear rate were 88.89%, 87.10%, 86.36%, 75%, 88.89%, significantly higher than the control group, the difference was statistically significant.Conclusion:At the same time: strengthening anti tuberculosis treatment with thymosin injection auxiliary enhancing immune function, help to improve the T cell subsets of patients, promote the clinical symptom remission, is worthy of clinical application
[Key words]Thymosin; diabetes mellitus complicated with pulmonary tuberculosis; immune effect